Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Chemomab Therapeutics (NasdaqCM:CMMB) FY Conference February 26, 2026 08:00 AM ET Speaker1Good morning, everyone, and welcome back to day two of Oppenheimer's 36th Annual Healthcare Conference. I'm Jeff Jones, one of the biotech analysts on the team here, and I am delighted to welcome Adi Mor, CEO of Chemomab Therapeutics, to give us an update on their story. Adi, I will hand it off to you.Speaker0Thank you very much, Jeff. My pleasure to be here today and presenting Chemomab at the Oppenheimer Conference. ...

HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL. FibroB ...

NAPLES, FL / ACCESS Newswire / February 26, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, launches Stemtech BioSciences E-Commerce Retail market channel. (Stemtech Corporation - OTCID:STEK) "Live Longer - Live Better - Live Younger" President & COO, John W. ...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed an agreement with Spaulding Rehabilitation (“Spaulding Rehabilitation”), a member of the Mass General Brigham healthcare system, for the provision of MDMA for use in a clinical trial investigating MDMA-assisted therapy for the trea ...

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. T ...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to d ...

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, Feb. 26, 2026 Â /PRNewswire/ --Â Im ...